Relevant Publications

Select Publications by Athersys and Collaborators

Reading JL, Sabbah S, Busch S, Tree TI: Mesenchymal stromal cells as a means of controlling pathological T-cell responses in allogeneic islet transplantation. Curr Opin Organ Transplant 2013 Feb;18(1):59-64. http://www.ncbi.nlm.nih.gov/pubmed/23222174


Ryu JC, Davidson BP, Xie A, Qi Y, Zha D, Belcik JT, et al.: Molecular Imaging of the Paracrine Proangiogenic Effects of Progenitor Cell Therapy in Limb Ischemia. Circulation. 2013 Jan 10. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/23307829


Bravery CA, J. Carmen, T. Fong, W. Oprea, et al.: Potency Assay Development for Cellular Therapy Products; An ISCT Review of the Requirements and Experiences in the Industry. Cytotherapy 2013 15: 9-19 http://www.ncbi.nlm.nih.gov/pubmed/23260082


Ting AE, Sherman W: Allogeneic stem cell transplantation for ischemicmyocardial dysfunction. Curr Opin Organ Transplant. 2012 Dec;17(6):675-80. http://www.ncbi.nlm.nih.gov/pubmed/23111647


Vaes B, Van’t Hof W, Deans RJ, Pinxteren J: Application of MultiStem allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front Immunol. 2012;3:345. Epub 2012 Nov 27. http://www.ncbi.nlm.nih.gov/pubmed/23205020


Jacobs SA, Pinxteren J, Roobrouck VD, Luyckx A, et al.: Human multipotent adult progenitor cells are non-immunogenic and exert potent immunomodulatory effects on alloreactive T cell responses. Cell Transplant. 2012 Oct 1. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/23031260


Walker PA, Bedi SS, Shah SK, Jimenez F, et al.: Intravenous multipotent adult progenitor cell therapy after traumatic brain injury: modulation of the resident microglia population. J Neuroinflammation. 2012 Sep 28;9:228. http://www.ncbi.nlm.nih.gov/pubmed/23020860


Lehman N, Cutrone R, Raber A, Perry R, et al.: Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Cytotherapy. Sep;14(8):994-1004 (2012) http://www.ncbi.nlm.nih.gov/pubmed/22687190


Medicetty S, Wiktor D, Lehman N, Raber A, et al.: Percutaneous adventitial delivery of allogeneic bone marrow-derived stem cells via infarct-related artery improves long-term ventricular function in acute myocardial infarction. Cell Transplant. 21(6):1109-20. Epub 2011 Oct 14 (2012) http://www.ncbi.nlm.nih.gov/pubmed/22004910


Nan Z, Shekels L, Ryabinin O, et al.: Intra-cerebroventricular transplantation of human bone marrow-derived multipotent progenitor cells in an immunodeficient mouse model of Mucopolysaccharidosis type I (MPS-I). Cell Transplant [epub ahead of print] (2012) http://www.ncbi.nlm.nih.gov/pubmed/22472595


Penn MS, Ellis S, Gandhi S, et al.: Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res 110(2):304-11 (2012) http://www.ncbi.nlm.nih.gov/pubmed/22052917


Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J et al.: Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I). J Transl Med 9:124; 2011. http://www.ncbi.nlm.nih.gov/pubmed/21798013


Busch SA,van Crutchen STJ, Deans RJ, Ting AE: Mesenchymal Stromal Cells as a Therapeutic Strategy to Support Islet Transplantation in Type 1 Diabetes Mellitus. Cell Medicine, Volume 2, Number 2, 2011, pp. 43-53(11). ingentaconnect Link


Busch SA, Hamilton JA, Horn KP, Cuascut FX, et al.: Multipotent adult progenitor cells prevent macro-phage mediated axonal dieback and promote regrowth after spinal cord injury. Journal of Neuroscience 31(3):944-953 (2011) http://www.ncbi.nlm.nih.gov/pubmed/21248119


DimomeletisI, Deindl E, Zaruba M, Groebner M, Zahler S. et al.: Assessment of human MAPCs for stem cell transplantation and cardiac regeneration after myocardial infarction in SCID mice. Experimental Hematology 38(11):1105-14 (2010) http://www.ncbi.nlm.nih.gov/pubmed/20621157


Aranguren XL, Pelacho B, Peñuelas I, Abizanda G, Uriz M, et al.: MAPC transplantation confers a more durable benefit than ACC133+ cell transplantation. Cell Transplant 2010 Aug 17 (E pub ahead of print) http://www.ncbi.nlm.nih.gov/pubmed/20719064


Walker PA, Shah SK, Jimenez F, Gerber MH, Xue H, et al.: Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: preserving the blood brain barrier via an interaction with splenocytes. Experimental Neurology 225:341–352 (2010) http://www.ncbi.nlm.nih.gov/pubmed/20637752


Mays RW, Borlongan CV, Yasuhara T et al.: Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke. J Exp Stroke Transl Med 3(1): 34-46 (2010) http://www.jestm.com/index.php/jestm/article/view/33


Jameel MN, Li Q, Qiang X et al.: Long-term functional improvement and gene expression changes after bone marrow-derived multipotent progenitor cell transplantation in myocardial infarction. Am J Physiol Heart Circ Physiol 298(5):H1348-56. (2010) http://www.ncbi.nlm.nih.gov/pubmed/20173039


Kovacsovics-Bankowski M, Streeter PR, Mauch KA et al.: Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol. 255(1-2):55-60 (2009) http://www.ncbi.nlm.nih.gov/pubmed/19022422


Wang X, Jameel MN, Li Q, Mansoor A, Qiang X, Swingen C, Panetta C, Zhang J. Stem cells for myocardial repair with use of a transarterial catheter. Circulation. 2009 Sep 15;120 (11 Suppl):S238-46 http://www.ncbi.nlm.nih.gov/pubmed/19752374


Highfill SL, Kelly RM, O'Shaughnessy MJ et al.: Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming Blood 114(3): 693–701 (2009) http://www.ncbi.nlm.nih.gov/pubmed/19458354


Boozer S, Lehman N, Lakshmipathy U et al.: Global characterization and genomic stability of human MultiStem, a multipotent adult progenitor cell. J Stem cells 4(1):17-28 (2009) http://www.ncbi.nlm.nih.gov/pubmed/20498688


Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 40(2):510-5. (2009) http://www.ncbi.nlm.nih.gov/pubmed/19095993


Kovacsovics-Bankowski M., Mauch K., Raber, A., et al.: Preclinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells. Cytotherapy 10:7,730 — 742 (2008) http://www.ncbi.nlm.nih.gov/pubmed/18985479


Yasuhara T, Hara K, Maki M, Mays RW et al.: Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats. J Cereb Blood Flow Metab 28 (11):1804-10. (2008) http://www.ncbi.nlm.nih.gov/pubmed/18594556


Hess DC, and Borlongan CV. Cell-based therapy in ischemic stroke. Expert Rev Neurother (8): 1193–1201 (2008) http://www.ncbi.nlm.nih.gov/pubmed/18671663


Mays R, Van't Hof W, Deans R, et al. Development of adult pluripotent stem cell therapies for ischemic injury and disease. Expert Opin. Biol. Ther. 7(2):173-184 (2007) http://www.ncbi.nlm.nih.gov/pubmed/17250456


Verfaillie CM, Blazar B, Weismann IL, et al. Hematopoetic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoetic stem cells. Journal of Experimental Medicine. 22;204(1):129-39 (2007) http://www.ncbi.nlm.nih.gov/pubmed/17227908


Van't Hof W, Mal N, Raber A, et al. Multipotent adult progenitor cells. Contemporary Cardiology: Stem Cells and Myocardial Regeneration. Penn MS(Ed.) Humana Press, Inc., MA, USA. 2006: 39-50.


Breyer A, Estharubadi N, Oki M, et al. Multipotent Adult Progenitor Cell(MAPC) isolation and culture procedures. Experimental Hematology 34(11): 1596-601 (2006) http://www.ncbi.nlm.nih.gov/pubmed/17046581


Yasuhara T, Matsukawa N, Yu G et al. Behavioral and histological characterization of intrahippocampal grafts of human bone marrow-derived multipotent progenitor cells in neonatal rats with hypoxic-ischemic injury. Cell Transplant. 2006 15(3):231-238. http://www.ncbi.nlm.nih.gov/pubmed/16719058


Verfaillie CM, Miler RF, Chen A, et al. Neuroectodermal differentiation from mouse multipotent adult progenitor cells. Proceedings of the National Academy of Sciences Early Edition. 2003; 10.1073/1834196100.


Keene CD, Ortiz-Gonzalez XR, Jiang Y, Largaespada DA et al.: Neural differentiation and incorporation of bone marrow-derived multipotent adult progenitor cells after single cell transplantation into blastocyst stage mouse embryos. Cell Transplant. 12(3):201-13 (2003) http://www.ncbi.nlm.nih.gov/pubmed/12797375


Verfaillie CM, Marker PH, Koodie L, et al. Origin of endothelial progenitors in human postnatal bone marrow. Journal of Clinical Investigation. 2002; 109:337-346. http://www.ncbi.nlm.nih.gov/pubmed/11827993


Verfaillie CM, Hu WS, Johnson S, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. Journal of Clinical Investigation. 2002; 109:1291-1302.


Verfaillie LM, Reyes M, Jiang Y, et al. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle and brain. Experimental Hematology. 2002; 30:896-904. http://www.ncbi.nlm.nih.gov/pubmed/12160841

Other Relevant Papers

Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW: Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunology and Cell Biology 91, 32-39; doi:10.1038/icb.2012.64 (2013)


Leistner DM, Zeiher AM. Novel avenues for cell therapy in acute myocardial infarction. Circ Res 110(2):195-7 (2012)


Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 17(7):796-808 (2011)


Beltrami AP, Cesselli D, Bergamin N, et al. Culture of multipotent cells from human tissues. Blood; online publication, May 24, 2007.


De Coppi P, Bartsch G Jr, Diddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 25(1):100-106 (2007)


Anjos-Afonso F, Bonnet D. Non-hematopoietic/endothelial SSEA-1 pos cells defines the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood. 109(3):1298-1306 (2007)


Kucia M, Reca R, Campbell FR, et al. A population of very small embryonic-like (VSEL)CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia. 20(5):857-869 (2006)


Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular(HUCPV) cells: a source of mesenchymal progenitors.

Stem Cells. 23(2):220-229 (2005)


Yoon YS, Wecker A, Heyd L et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J. Clin. Invest. 115(2):326-338 (2005)


D'Ippolito G, Diabira S, Howard GA et al. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J. Cell Sci. 117(Pt 14):2971-2981 (2004)


Kogler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J. Exp. Med. 200(2):123-135 (2004)

Select Publications by Athersys and Collaborators

Anderson JT, Campbell M, Wang J, Brunden KR, Harrington JJ, et al. Investigation of 4-piperidinols as novel H3 antagonists. Bioorg Med Chem Lett 20(21):6246-9. (2010) http://www.ncbi.nlm.nih.gov/pubmed/20833043


Tuney LN, Robarge MJ, Gleason E, Song J, Murphy SM, et al. 3-Indolyl sultams as selective CRTH2 antagonists. Bioorg Med Chem Lett 20(11):3287-90. (2010) http://www.ncbi.nlm.nih.gov/pubmed/20457519


Pi M, Chen L, Huang MZ, Zhu W, Ringhofer B et al. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One 3(12):e3858 (2008) http://www.ncbi.nlm.nih.gov/pubmed/19050760


Murphy SM, Palmer M, Poole MF, Padegimas L, Hunady K, Danzig J, Gill S, Gill R, Ting A, Sherf B, Brunden K and Stricker-Krongrad A. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J. Pharmacol. Toxicol. Methods. 54:42-55 (2006) http://www.ncbi.nlm.nih.gov/pubmed/16326118


Huck BR, Llamas L, Robarge MJ, Dent TC, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR, and Bennani YL. The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists. Bioorganic Med. Chem. Letters.16:2891-2894 (2006) http://www.ncbi.nlm.nih.gov/pubmed/16546379


Huck BR, Llamas L, Robarge MJ, Dent TC, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR and Bennani YL. The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist. Bioorganic Med. Chem. Letters. 16:4130-4134 (2006) http://www.ncbi.nlm.nih.gov/pubmed/16750364


Song J, Hanniford D, Doucette C, Graham E, Poole MF, Ting A, et al. Development of homogeneous high affinity agonist binding assays for 5HT-2 receptor subtypes. Assay Drug Dev Technol. 3(6):649-59 (2005) http://www.ncbi.nlm.nih.gov/pubmed/16438660


Brunden KR, Sherf BA and Harrington JJ. The Application of RAGE and GECKO in Cell-based Target Discovery Screens. Pharmacogenomics. 6:383-392 (2005) http://www.ncbi.nlm.nih.gov/pubmed/16004556


Song J, Doucette C, Hanniford D, Hunady K, Wang N, Sherf B, Harrington JJ, Brunden KR and Stricker-Krongrad A. Generation of Cell Lines for Drug Discovery Through Random Amplification of Gene Expression (RAGE): Application to the Human Histamine H3 Receptor. Assay and Drug Development Technol. 3:309-318 (2005) http://www.ncbi.nlm.nih.gov/pubmed/15971992


Pi M, Faber P, Ekema G, Jackson PD, Ting A, Wang N, et al. Identification of a novel extracellular cation-sensing G-protein coupled receptor. J Biol Chem. 280(48):40201-9 (2005) http://www.ncbi.nlm.nih.gov/pubmed/16199532


Jackson PD, Harrington JJ. High throughput target discovery using cell-based genetics. Drug Discov Today 10(1):53-60 (2005) http://www.ncbi.nlm.nih.gov/pubmed/15676299


Anderson JT, Ting AE, Boozer S, Brunden KR, Danzig J, Dent T, Harrington JJ, Murphy SM, Perry R, Raber A, Rundlett SE, Wang J, Wang N, and Bennani YL. The discovery of S-phase arresting agents derived from noscapine. J. Med. Chem. 48:2756-2758 (2005) http://www.ncbi.nlm.nih.gov/pubmed/15828811


Robarge MJ, Bom DC, Tumey LN, Varga N, Gleason E, Silver D, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf BA, Mays RW, Stricker-Krongrad A, Brunden KR, Harrington JJ and Bennani YL. Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists. Bioorganic Med. Chem. Letters 15(6):1749-1753 (2005) http://www.ncbi.nlm.nih.gov/pubmed/15745833


Tumey LN, Bom D, Huck B, Gleason E, Wang J, Silver D, Brunden KR, Boozer S, Rundlett S, Sherf B, Harrington J, Murphy S, Dent T, Leventhal C, Bailey A, and. Bennani, YL. The identification and optimization of a N-hydroxy urea series of Flap Endonuclease 1 inhibitors. Bioorganic & Med. Chem. Letters. 15:277-281 (2004) http://www.ncbi.nlm.nih.gov/pubmed/15603939


Tumey LN, Huck B, Gleason E, Wang J, Silver D, Brunden KR, Boozer S, Rundlett, S, Sherf, B, Murphy S, Harrington J, Dent T, Leventhal C, Bailey A, and Bennani, YL. The identification and optimization of 2,4-diketobutyric acids as Flap Endonuclease 1 inhibitors. Bioorganic & Med. Chem. Letters. 14:4915-4918 (2004) http://www.ncbi.nlm.nih.gov/pubmed/15341951


Jin G, Klika A, Callahan M, Faga B, Danzig J, et al. Identification of a human NF-κB-activating protein TAB3. Proceedings of the National Academy of Sciences. 101.7:2028-33 (2004) http://www.ncbi.nlm.nih.gov/pubmed/14766965


Harrington J, Brunden KR. Drug screening in the genomics era. Current Drug Discovery. 2002; Jan:17-20.

Other Relevant Papers

Hajjo R, Grulke CM, Golbraikh A, Setola V, Huang XP, Roth BL, Tropsha A. Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvuloptahic compounds among common drugs. J Med Chem. 11;53(21):7573-86 (2010) http://www.ncbi.nlm.nih.gov/pubmed/20958049


Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, and Pezzoli G. regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther. 2010 Jun 11 [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/20553285


Huang XP, Setola V, Yadav PN, Allen JA, and Rogan SC et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine (2B) receptor agonists: implications for dug safety assessment. Mol Pharmacol 76(4):710-22 (2009) http://www.ncbi.nlm.nih.gov/pubmed/19570945


Roth BL. Drugs and valvular heart disease. N Engl J Med. 356;1: 6 – 9 (2007) http://www.ncbi.nlm.nih.gov/pubmed/17202450


Schade R, Andersoh F, et al. Dopamine agonists and the risk of cardiac valve regurgitation. N Engl J Med 356;1:29 – 38 (2007) http://www.ncbi.nlm.nih.gov/pubmed/17202453


Zanettini R, Antonini A, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 356;1:39 – 46 (2007) http://www.ncbi.nlm.nih.gov/pubmed/17202454


Van der Goot H, Timmerman H. Selective ligands as tools to study histamine receptors. Eur J Med Chem. 35:5 – 20 (2000) http://www.ncbi.nlm.nih.gov/pubmed/10733599